copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Capitalizing Biotech Innovation: Aphios’ Hybrid Business Model . . . Aphios® Corporation is an emerging growth biotechnology company advancing health through sustainable science We integrate green enabling technology platforms with biotechnology to improve drug discovery and manufacturing, nanotechnology drug delivery, and pathogen safety
Careers at Aphios – Careers – About Us – Aphios – Aphios At Aphios Corporation, you will be part of a dynamic team dedicated to developing solutions for unmet medical needs, and improving quality of life, health and wellness Aphios offers competitive compensation packages and challenging positions with opportunities for career growth
About Us – Management and Directors – Aphios – Aphios President and CEO, Aphios Corporation Val R Livada, Ph D Dr Val R Livada, Ph D is Founder and CEO of Weybridge Partners, Winchester, MA, which is focused on successful technology commercialization, and a Senior Lecturer in Corporate entrepreneurship at the Sloan School of Management, MIT, Cambridge, MA At MIT, he has led a joint research
Company Overview - Aphios Aphios’ business model is designed to develop enabling technologies and enhanced therapeutics for maintaining health and resolving unmet medical needs while maximizing profitability and minimizing risks
Contact - Aphios Aphios Corporation 87 Main Street North Reading MA 01864 USA Telephone (001) (781) 932-6933 E-mail: mail@aphios com
Individual, Institutional and Corporate Investors - Aphios Aphios® Corporation has been self-funded to date with Founders’ capital, employee stock ownership, grants and contracts from the National Institutes of Health and other institutions, collaborative and contract research with emerging biotechnology and multinational companies, and product sales to biotechnology companies and research chemical
Aphios Granted US Patent for Combination HIV Latency Nanoparticles . . . Woburn, Mass – May 15, 2024 − Aphios Corporation announced today that it has been granted US Patent No 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases More than 35 million people have died from AIDS, and 37 million people are living with HIV worldwide
Aphios Awarded NIH SBIR Grant For Development of Anti-CCR5 . . . North Reading, Mass – December 11, 2024 − Aphios announced today that it was awarded an NIH SBIR grant from the National Institute on Aging (NIA) to develop anti-CCR5 nanoparticles to treat Alzheimer’s disease